Terms: = Kidney tumors AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862
276 results:
1. Multiple and hereditary renal tumors: a review for radiologists.
Corral de la Calle MÁ; Encinas de la Iglesia J; Fernández Pérez GC; Fraino A; Repollés Cobaleda M
Radiologia (Engl Ed); 2024; 66(2):132-154. PubMed ID: 38614530
[TBL] [Abstract] [Full Text] [Related]
2. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
Rosellini M; Mollica V; Marchetti A; Coluccelli S; Giunchi F; Tassinari E; Ricci C; Fiorentino M; Tallini G; De Biase D; Massari F
Pathol Res Pract; 2024 Feb; 254():155142. PubMed ID: 38277752
[TBL] [Abstract] [Full Text] [Related]
3. Genetic Profiling Uncovers Genome-Wide Loss of Heterozygosity and Provides Insight into Mechanisms of Sarcomatoid Transformation in Chromophobe Renal Cell Carcinoma.
Collins K; Acosta AM; Siegmund SE; Cheng L; Hirsch MS; Idrees MT
Mod Pathol; 2024 Feb; 37(2):100396. PubMed ID: 38043790
[TBL] [Abstract] [Full Text] [Related]
4. Circpten suppresses human clear cell renal carcinoma progression and resistance to mTOR inhibitors by targeting epigenetic modification.
Zhan Y; Liu Y; Yang R; Chen Q; Teng F; Huang Y; Jiang X; Wang Y; Yu B; Zhang D; Bao L; Liu X; Huang J
Drug Resist Updat; 2023 Nov; 71():101003. PubMed ID: 37866104
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT.
Ricci C; Ambrosi F; Franceschini T; Giunchi F; Grillini A; Franchini E; Grillini M; Schiavina R; Massari F; Mollica V; Tateo V; Bianchi FM; Bianchi L; Droghetti M; Maloberti T; Tallini G; Colecchia M; Acosta AM; Lobo J; Trpkov K; Fiorentino M; de Biase D
Virchows Arch; 2023 Nov; 483(5):687-698. PubMed ID: 37845471
[TBL] [Abstract] [Full Text] [Related]
6. Deciphering key genes involved in cisplatin resistance in kidney renal clear cell carcinoma through a combined
Malik M; Maqbool M; Nisar T; Akhter T; Ujan JA; Algarni AS; Joufi FAA; Alanazi SSK; Almotared MH; Bekhit MMS; Jamil M
Oncol Res; 2023; 31(6):899-916. PubMed ID: 37744271
[TBL] [Abstract] [Full Text] [Related]
7. Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma.
Xiang J; Liu W; Liu S; Wang T; Tang H; Yang J
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16015-16030. PubMed ID: 37689589
[TBL] [Abstract] [Full Text] [Related]
8. Chromophobe renal cell carcinoma.
Henske EP; Cheng L; Hakimi AA; Choueiri TK; Braun DA
Cancer Cell; 2023 Aug; 41(8):1383-1388. PubMed ID: 37541245
[TBL] [Abstract] [Full Text] [Related]
9. PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
Rezaei S; Nikpanjeh N; Rezaee A; Gholami S; Hashemipour R; Biavarz N; Yousefi F; Tashakori A; Salmani F; Rajabi R; Khorrami R; Nabavi N; Ren J; Salimimoghadam S; Rashidi M; Zandieh MA; Hushmandi K; Wang Y
Eur J Pharmacol; 2023 Sep; 955():175909. PubMed ID: 37490949
[TBL] [Abstract] [Full Text] [Related]
10. Renal Neoplasia Occurring in Patients With pten Hamartoma Tumor Syndrome : Clinicopathologic Study of 12 Renal Cell Carcinomas From 9 Patients and Association With Intrarenal "Lipomas".
Kozman D; Kao CS; Nguyen JK; Smith SC; Kehr EL; Tretiakova M; Przybycin CG; Williamson SR; Argani P; Eng C; Campbell SC; McKenney JK; Alaghehbandan R
Am J Surg Pathol; 2023 Sep; 47(9):1001-1010. PubMed ID: 37357918
[TBL] [Abstract] [Full Text] [Related]
11. Longitudinal Analysis of Cancer Risk in Children and Adults With Germline pten Variants.
Yehia L; Plitt G; Tushar AM; Joo J; Burke CA; Campbell SC; Heiden K; Jin J; Macaron C; Michener CM; Pederson HJ; Radhakrishnan K; Shin J; Tamburro J; Patil S; Eng C
JAMA Netw Open; 2023 Apr; 6(4):e239705. PubMed ID: 37093598
[TBL] [Abstract] [Full Text] [Related]
12. Adaptive Immunity in Genitourinary Cancers.
Koti M; Bivalacqua T; Black PC; Cathomen T; Galsky MD; Gulley JL; Ingersoll MA; Kamat AM; Kassouf W; Siemens DR; Gao J
Eur Urol Oncol; 2023 Jun; 6(3):263-272. PubMed ID: 37069029
[TBL] [Abstract] [Full Text] [Related]
13. Comprehensive Genomic Profiling of NF2-Mutated kidney tumors Reveals Potential Targets for Therapy.
Hacking SM; Pavlick D; Wang Y; Carneiro BA; Mullally M; Lu S; Canepa M; Bratslavsky G; Jacob J; Necchi A; Spiess PE; Wang L; Yakirevich E; Ross J
Oncologist; 2023 Jul; 28(7):e508-e519. PubMed ID: 36917021
[TBL] [Abstract] [Full Text] [Related]
14. LncRNA GABPB1-IT1 inhibits the tumorigenesis of renal cancer via the miR-21/pten axis.
Tan C; Du H; Wang Y; Zhao J; Cheng X; Lan H
J Biochem Mol Toxicol; 2023 Apr; 37(4):e23288. PubMed ID: 36756790
[TBL] [Abstract] [Full Text] [Related]
15. A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.
Huang RH; Hong YK; Du H; Ke WQ; Lin BB; Li YL
J Transl Med; 2023 Jan; 21(1):20. PubMed ID: 36635710
[TBL] [Abstract] [Full Text] [Related]
16. An Overview of Epigenetics in Clear Cell Renal Cell Carcinoma.
Grammatikaki S; Katifelis H; Farooqi AA; Stravodimos K; Karamouzis MV; Souliotis K; Varvaras D; Gazouli M
In Vivo; 2023; 37(1):1-10. PubMed ID: 36593023
[TBL] [Abstract] [Full Text] [Related]
17. A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer.
Shore N; Mellado B; Shah S; Hauke R; Costin D; Adra N; Cullberg M; Teruel CF; Morris T
Clin Genitourin Cancer; 2023 Apr; 21(2):278-285. PubMed ID: 36572571
[TBL] [Abstract] [Full Text] [Related]
18. BAP1 and pten mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study.
Friedhoff J; Schneider F; Jurcic C; Endris V; Kirchner M; Sun A; Bolnavu I; Pohl L; Teroerde M; Kippenberger M; Schwab C; Kaczorowski A; Zschäbitz S; Jäger D; Hohenfellner M; Stenzinger A; Duensing A; Duensing S
Cancer Immunol Immunother; 2023 Jun; 72(6):1603-1618. PubMed ID: 36562826
[TBL] [Abstract] [Full Text] [Related]
19. Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
Ackroyd SA; Arguello D; Ramos P; Mahdi H; ElNaggar A; Winer I; Holloway R; Krivak T; Jones N; Turner VG; Herzog T; Chu C; Brown J; Mantia-Smaldone G
Gynecol Oncol; 2023 Feb; 169():164-171. PubMed ID: 36333181
[TBL] [Abstract] [Full Text] [Related]
20. Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity.
Williamson SR; Hes O; Trpkov K; Aggarwal A; Satapathy A; Mishra S; Sharma S; Sangoi A; Cheng L; Akgul M; Idrees M; Levin A; Sadasivan S; San Miguel Fraile P; Rogala J; Comperat E; Berney DM; Bulimbasic S; McKenney JK; Jha S; Sampat NY; Mohanty SK
Histopathology; 2023 Jan; 82(2):296-304. PubMed ID: 36208048
[TBL] [Abstract] [Full Text] [Related]
[Next]
